UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
PURPOSE: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133 have been posited as possible stem cell like cancer cells (SCLCC), a potential source of drug r...
Main Authors: | Adele P. Williams, Evan F. Garner, Laura L. Stafman, Jamie M. Aye, Colin H. Quinn, Raoud Marayati, Jerry E. Stewart, Venkatram R. Atigadda, Elizabeth Mroczek-Musulman, Blake P. Moore, Elizabeth A. Beierle, Gregory K. Friedman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-10-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319302670 |
Similar Items
-
9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
by: Raoud Marayati, et al.
Published: (2021-01-01) -
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
by: Evan F. Garner, et al.
Published: (2018-05-01) -
PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
by: Laura L Stafman, et al.
Published: (2019-01-01) -
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
by: Laura L. Stafman, et al.
Published: (2019-09-01) -
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.
by: Laura V Bownes, et al.
Published: (2021-01-01)